BRPI0807290A2 - "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma" - Google Patents

"composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma"

Info

Publication number
BRPI0807290A2
BRPI0807290A2 BRPI0807290A BRPI0807290A BRPI0807290A2 BR PI0807290 A2 BRPI0807290 A2 BR PI0807290A2 BR PI0807290 A BRPI0807290 A BR PI0807290A BR PI0807290 A BRPI0807290 A BR PI0807290A BR PI0807290 A2 BRPI0807290 A2 BR PI0807290A2
Authority
BR
Brazil
Prior art keywords
transdermal absorption
medical composition
storage unit
same
preparation
Prior art date
Application number
BRPI0807290A
Other languages
English (en)
Inventor
Kimura Takahito
Original Assignee
Teika Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teika Pharmaceutical Co Ltd filed Critical Teika Pharmaceutical Co Ltd
Publication of BRPI0807290A2 publication Critical patent/BRPI0807290A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0807290A 2007-03-02 2008-02-29 "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma" BRPI0807290A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007053102 2007-03-02
PCT/JP2008/053597 WO2008108286A1 (ja) 2007-03-02 2008-02-29 経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤

Publications (1)

Publication Number Publication Date
BRPI0807290A2 true BRPI0807290A2 (pt) 2016-10-11

Family

ID=39738169

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807290A BRPI0807290A2 (pt) 2007-03-02 2008-02-29 "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma"

Country Status (10)

Country Link
US (1) US9326979B2 (pt)
EP (1) EP2123274B1 (pt)
JP (2) JP5313868B2 (pt)
KR (2) KR101521989B1 (pt)
CN (1) CN101621999B (pt)
BR (1) BRPI0807290A2 (pt)
CA (1) CA2679316C (pt)
ES (1) ES2591278T3 (pt)
RU (1) RU2428186C2 (pt)
WO (1) WO2008108286A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
IN2012DN00570A (pt) * 2009-07-14 2015-06-12 Polypid Ltd
KR101080729B1 (ko) 2009-11-30 2011-11-07 현대자동차주식회사 차량의 럼버서포트 장치
EP2525778B1 (en) 2010-01-19 2018-08-01 Polypid Ltd. Sustained-release nucleic acid matrix compositions
WO2011111384A1 (ja) * 2010-03-11 2011-09-15 株式会社メドレックス パーキンソン病治療薬を含有する経皮用組成物
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DE102011076653A1 (de) * 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
EP2838536B1 (en) * 2012-04-18 2017-08-09 Mallinckrodt LLC Immediate release pharmaceutical compositions with abuse deterrent properties
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
JP2014141531A (ja) * 2014-05-10 2014-08-07 Isao Kajisa 完成版がん根絶経口薬
WO2016004170A1 (en) 2014-07-03 2016-01-07 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US20180326061A1 (en) * 2015-11-06 2018-11-15 Bkr Ip Holdco Llc Modified transdermal delivery device or patch and method of delivering insulin from said modified transdermal delivery device
EP3178343B8 (fr) * 2015-12-08 2019-08-07 Omega SA Bracelet
TW201840307A (zh) 2017-03-24 2018-11-16 美商伊英克加利福尼亞有限責任公司 用於遞送活性分子的微胞系統
WO2019099323A1 (en) * 2017-11-14 2019-05-23 E Ink California, Llc Microcell systems for delivering hydrophilic active molecules
US11266832B2 (en) 2017-11-14 2022-03-08 E Ink California, Llc Electrophoretic active delivery system including porous conductive electrode layer
EP3856160A4 (en) 2018-09-25 2022-07-06 SpecGx LLC ABUSE-PROOF IMMEDIATE RELEASE CAPSULE DOSAGE FORMS
KR102797900B1 (ko) 2019-11-27 2025-04-21 이 잉크 코포레이션 전기 침식 밀봉층을 갖는 마이크로셀들을 포함하는 유익제 전달 시스템
CN112315782B (zh) * 2020-10-20 2022-08-12 南京理工大学 一种基于热溶质毛细对流原理的电子艾灸仪
EP4236927A4 (en) 2020-10-29 2024-10-16 E Ink Corporation MICROCELL SYSTEMS FOR DELIVERY OF HYDROPHILIC ACTIVE MOLECULES
EP4236926A4 (en) 2020-10-29 2024-08-28 E Ink Corporation MICROCELL SYSTEMS FOR DELIVERY OF BENEFICIAL AGENTS
CN116077419B (zh) * 2023-02-24 2023-10-27 丽珠集团新北江制药股份有限公司 一种犬用盐酸司来吉兰透皮吸收剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2156215B (en) * 1984-03-05 1988-03-02 Nitto Electric Ind Co Percutaneous absorption type adhesive pharmaceutical preparation
JP2775053B2 (ja) 1988-08-19 1998-07-09 塩野義製薬株式会社 モルフィン類を含有する外用製剤
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
JP2669951B2 (ja) 1991-03-28 1997-10-29 雍憲 森本 麻薬性鎮痛剤を含有する経皮吸収組成物
JP2843923B2 (ja) 1991-05-11 1999-01-06 久光製薬株式会社 経皮吸収組成物
JPH0648962A (ja) * 1991-10-24 1994-02-22 Kazutoshi Morimoto 経皮吸収製剤用組成物
JP3280711B2 (ja) 1992-08-26 2002-05-13 積水化学工業株式会社 経皮吸収製剤
JP3514480B2 (ja) * 1993-01-06 2004-03-31 塩野義製薬株式会社 モルフィン類を含有する外用製剤
US5503844A (en) * 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
JPH0733681A (ja) * 1993-05-18 1995-02-03 Sekisui Chem Co Ltd 経皮吸収貼付剤
JPH07300418A (ja) 1994-03-11 1995-11-14 Sekisui Chem Co Ltd 経皮吸収貼付剤
WO1995024197A1 (en) * 1994-03-11 1995-09-14 Sekisui Chemical Co., Ltd. Percutaneously absorbable plaster comprising acid-addition salt of morphine
JPH08143458A (ja) 1994-11-17 1996-06-04 Sekisui Chem Co Ltd 経皮吸収貼付剤
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9605867D0 (en) 1996-03-20 1996-05-22 Svedman Paul Transdermal device
AU733564B2 (en) 1997-09-16 2001-05-17 Teijin Limited Gel-form pressure-sensitive adhesive, and adhesive material and adhesive medicinal preparation both containing the same
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
CN1320145A (zh) 1998-07-29 2001-10-31 帝人株式会社 粘着性组合物、以及含有该组合物的透湿性粘着带、粘着性药物组合物以及粘着带制剂
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
JP2001151668A (ja) 1999-11-22 2001-06-05 Jcr Pharmaceuticals Co Ltd 経皮吸収製剤
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
JP4641394B2 (ja) * 2004-08-06 2011-03-02 リンテック株式会社 経皮吸収型製剤の製造方法
SI1814531T1 (sl) * 2004-10-21 2010-10-29 Durect Corp Transdermalni dostavni sistem
JP2006248996A (ja) * 2005-03-10 2006-09-21 Nitto Denko Corp 経皮吸収型貼付剤

Also Published As

Publication number Publication date
KR20090116816A (ko) 2009-11-11
US20100074943A1 (en) 2010-03-25
CA2679316C (en) 2016-11-29
WO2008108286A1 (ja) 2008-09-12
CN101621999B (zh) 2012-09-26
JP2013189451A (ja) 2013-09-26
EP2123274A1 (en) 2009-11-25
KR20150017390A (ko) 2015-02-16
RU2428186C2 (ru) 2011-09-10
WO2008108286A9 (ja) 2009-10-08
KR101521989B1 (ko) 2015-05-28
JP5313868B2 (ja) 2013-10-09
EP2123274A4 (en) 2013-05-29
HK1134041A1 (en) 2010-04-16
CA2679316A1 (en) 2008-09-12
US9326979B2 (en) 2016-05-03
CN101621999A (zh) 2010-01-06
RU2009136444A (ru) 2011-04-10
JPWO2008108286A1 (ja) 2010-06-17
EP2123274B1 (en) 2016-08-24
ES2591278T3 (es) 2016-11-25
KR101612901B1 (ko) 2016-04-15

Similar Documents

Publication Publication Date Title
BRPI0807290A2 (pt) "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma"
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
BRPI0822121A2 (pt) Composição para cuidado oral, e uso da mesma
BRPI0809260A2 (pt) Dispositivo para a assistência médica de um paciente em uma emergência
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0811436A2 (pt) Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto.
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
IL201796A (en) Indole-3-Inglet or its pharmaceutical salts for use in the treatment of dermal lesion caused by papillomavirus
BRPI0815894A2 (pt) Composição farmacêutica, uso da mesma, e, sais farmaceuticamente aceitáveis de um composto.
DK1881820T3 (da) Engangsdispenser til patientinfusion
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
IL196869A0 (en) A pharmaceutical composition containing a hexahydrophenanthridin-2-ol derivative in combination with another active ingredient for treatment of diabetes mellitus
IL228904A0 (en) Use of milankiperan, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
ATE493119T1 (de) Pharmazeutische zusammensetzung
FR2934156B1 (fr) Medicament appetissant a administration orale sous forme solide
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0818483A2 (pt) Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0816392A2 (pt) composição para o cuidado doméstico e de tecidos, e, método para a coloração da mesma.
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2503 DE 26-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]